FilingReader Intelligence
Windlas Biotech achieves record revenue, expands capacity, rewards shareholders
July 5, 2025 at 12:29 PM UTC•By FilingReader AI
** Windlas Biotech (BSE: 543329) announced record revenue of INR7,599 million for the fiscal year 2025, a 20% increase year-over-year, driven by growth across its CDMO, Trade Generics, and Export verticals. The company also achieved its highest-ever EPS of INR29.19 and EBITDA of INR941 million, along with robust liquidity of INR2,131 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
BSE:WINDLAS•Bombay Stock Exchange
News Alerts
Get instant email alerts when Windlas Biotech publishes news
Free account required • Unsubscribe anytime